AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)
MT-2-02
Phase 2 other active
Quick answer
AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT) for CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) is a Phase 2 program (other) at Minoryx Therapeutics S.L. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Minoryx Therapeutics S.L.
- Indication
- CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD)
- Phase
- Phase 2
- Modality
- other
- Status
- active